Bioengineered Cardiac Tissue for Hypoplastic Left Heart Syndrome Analysis


About this study

The purpose of this study is to produce and characterize patient-specific cardiac tissue for Hypoplastic Left Heart Syndrome (HLHS) using reprogrammed cell technology.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients age 0-100 yrs. with clinically diagnosed hypoplastic left heart syndrome (HLHS) undergoing planned surgical repair and unaffected adult biological parents and/or siblings.

Exclusion Criteria:

  • Subjects with allergy to subcutaneous lidocaine, bupivicaine, or epinephrine. 


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Timothy Nelson, M.D., Ph.D.

Open for enrollment

Contact information:

Karen Miller CCRP

(507) 266-5510

More information


Publications are currently not available